View Future GrowthThis company is no longer activeThe company may no longer be operating, as it may be out of business. Find out why through their latest events.See Latest EventsA SPAC I Acquisition 過去の業績過去 基準チェック /06AC I Acquisitionの収益は年平均-238%で減少しているが、Capital Markets業界はgrowingで6.5%年平均の収益となった。主要情報-237.99%収益成長率2,472.89%EPS成長率Capital Markets 業界の成長10.26%収益成長率n/a株主資本利益率n/aネット・マージンn/a前回の決算情報31 Dec 2023最近の業績更新更新なしすべての更新を表示Recent updatesお知らせ • Apr 04+ 1 more updateNewGenIvf Limited completed the acquisition of A SPAC I Acquisition Corp. (NasdaqCM:ASCA) from A SPAC (Holdings) Acquisition Corp. and others in reverse merger transaction.NewGenIvf Limited entered into a merger agreement to acquire A SPAC I Acquisition Corp. (NasdaqCM:ASCA) from A SPAC (Holdings) Acquisition Corp. and others in reverse merger transaction for $50 million on February 15, 2023. Pursuant to the terms of the merger agreement, the aggregate consideration to be paid to existing shareholders of the Company is $50 million, which will be paid entirely in stock, comprised of newly issued Class A ordinary shares of ASCA at a price of $10.00 per share. Upon the effectiveness of the Acquisition Merger, the issued and outstanding Company Shares will be cancelled and automatically converted into the right to receive, without interest, the applicable portion of the Closing Payment Shares for such number of Company Shares. After the Closing, subject to the terms and conditions set forth in the merger agreement, the Principal Shareholders shall have the right to receive in the aggregate up to an additional 2 million ASCA Class A Ordinary Shares as earnout (subject to equitable adjustment for share splits, share dividends, combinations, recapitalizations and the like after the Closing, including to account for any equity securities into which such shares are exchanged or converted). As a result of the transaction, the combined company is expected to be renamed First Fertility Group Ltd. and remain a publicly listed company on the Nasdaq Stock Market. Following the close of the transaction, the combined company will continue to be led by Siu Wing Fung Alfred as Chairman and founder and Tina Fong as Director and co-founder of NewGen. On June 12, 2023, ASCA entered into a First Amendment to Merger Agreement, pursuant to which NewGen has agreed to provide non-interest bearing loans in an aggregate principal amount of up to $0.56 million to ASCA to fund any amount that may be required in order to further extend the period of time available for ASCA to consummate a business combination and for ASCA’s working capital, payment of professional, administrative and operational fees and expenses, and other purposes. In addition, pursuant to the First Amendment, subject to receipt of at least $140,000 as part of the Loan from NewGen, ASCA agreed to waive its termination rights and the right to receive any Break-up Fee due to NewGen’s failure to deliver the U.S. GAAP Financials by February 28, 2023. The transaction is subject to, among other things, regulatory approvals, the approval by ASCA's shareholders of the transaction and satisfaction or waiver of other customary closing conditions, the Key Personnel shall have executed the employment agreements, the SEC shall have declared the Registration Statement effective and immediately after the closing, ASCA shall have in excess of $5,000,000 in net tangible assets, the directors designated by the NewGenIvf shall have been appointed to the board of directors of the ASCA., additional listing application for the closing payment shares shall have been approved for listing by Nasdaq and additional agreements including Lock-up agreements, the registration rights agreement, voting and support agreements, the employment agreements and the non-competition agreements duly executed by all parties. The NewGen and ASCA Boards of Directors have unanimously approved the proposed transaction, which is expected to be completed in the third quarter of 2023. As of April 11, 2023, ASCA extended the outside date from April 17, 2023 to May 17, 2023 to complete the transaction. As of May 11, 2023, ASCA made a deposit of $90,000 (the “Extension Payment”) to the trust account and extended the period of time the Company has to consummate an initial business combination from May 17, 2023 to June 17, 2023. Following the deposit of the Extension Payment, the amount of funds remaining in the trust account was $38.1 million. As of October 11, 2023, ASCA made a deposit of $20,000 (the “Extension Payment”) to the trust account and extended the period of time the Company has to consummate an initial business combination from October 17, 2023 to November 17, 2023. Following the deposit of the Extension Payment, the amount of funds remaining in the trust account was approximately $39.3 million. As on March 4, 2024, the transaction was approved by shareholders of A SPAC I Acquisition Corp. Giovanni Caruso of Loeb & Loeb LLP acted as legal advisor to A SPAC I Acquisition Corp. (NasdaqCM:ASCA). Guangqin Wei and Chris G. Tang of Jun He Law Offices acted as legal advisor to NewGenIvf Limited. Kalikova & Associates, Haiwen & Partners LLP, DFDL (Thailand) Limited and Ogier acted as legal advisor to A SPAC I Acquisition Corp. (NasdaqCM:ASCA). NewGenIvf Limited completed the acquisition of A SPAC I Acquisition Corp. (NasdaqCM:ASCA) from A SPAC (Holdings) Acquisition Corp. and others in reverse merger transaction on April 3, 2024.Valuation Update With 7 Day Price Move • Mar 22Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to US$9.08, the stock trades at a trailing P/E ratio of 45.8x. Average trailing P/E is 19x in the Capital Markets industry in the US. Total loss to shareholders of 14% over the past year.Valuation Update With 7 Day Price Move • Mar 07Investor sentiment improves as stock rises 16%After last week's 16% share price gain to US$11.34, the stock trades at a trailing P/E ratio of 57.2x. Average trailing P/E is 19x in the Capital Markets industry in the US. Total returns to shareholders of 9.0% over the past year.Board Change • Dec 31High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. Chairman, CEO & CFO Claudius Tsang is the most experienced director on the board, commencing their role in 2021. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.お知らせ • Nov 11A SPAC I Acquisition Receives Letter from Nasdaq Due to Not Maintains Minimum of 300 Public Holders for Continued Listing in Accordance Nasdaq Listing Rule 5550(a)(3)On November 7, 2023, A SPAC I Acquisition Corp. (the ‘Company’) received a letter from The Nasdaq Stock Market LLC (‘Nasdaq’), which stated that the Company no longer complies with Nasdaq’s continued listing rules on The Nasdaq Capital Market due to the Company not having maintained a minimum of 300 public holders for continued listing, as required pursuant to Nasdaq Listing Rule 5550(a)(3). In accordance with the Nasdaq listing rules, the Company has 45 calendar days to submit a plan to regain compliance and, if Nasdaq accepts the plan, Nasdaq can grant the Company an extension of up to 180 calendar days from the date of the letter to evidence compliance. The Company plans to submit a compliance plan within the specified period.お知らせ • Aug 17A SPAC I Acquisition Corp. announced delayed 10-Q filingOn 08/15/2023, A SPAC I Acquisition Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Jun 14A SPAC I Acquisition Corp. announced that it has received $0.2 million in funding from A SPAC (Holdings) Acquisition Corp.A SPAC I Acquisition Corp. announced a private placement of a convertible unsecured promissory note at an issue price of $200,000 for gross proceeds of $200,000 on June 12, 2023. The transaction included participation from returning investor, A SPAC (Holdings) Acquisition Corp. The note shall be payable promptly on demand and, in any event, no later than the date on which the company terminates or consummates an initial business combination. Such note is convertible into warrants having the same terms and conditions as the public warrants, at the price of $1.00 per warrant, at the option of the investor. The note does not bear interest.お知らせ • May 18A SPAC I Acquisition Corp. announced delayed 10-Q filingOn 05/17/2022, A SPAC I Acquisition Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Apr 01A SPAC I Acquisition Corp. announced delayed annual 10-K filingOn 03/31/2022, A SPAC I Acquisition Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC.収支内訳A SPAC I Acquisition の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史NasdaqCM:ASCA 収益、費用、利益 ( )USD Millions日付収益収益G+A経費研究開発費31 Dec 230-13030 Sep 23011030 Jun 23011031 Mar 23011031 Dec 22011030 Sep 220000質の高い収益: ASCAは現在利益が出ていません。利益率の向上: ASCAは現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: ASCAの過去 5 年間の前年比収益成長率がプラスであったかどうかを判断するにはデータが不十分です。成長の加速: ASCAの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: ASCAは利益が出ていないため、過去 1 年間の収益成長をCapital Markets業界 ( 34.6% ) と比較することは困難です。株主資本利益率高いROE: ASCAの負債は資産を上回っているため、自己資本利益率を計算することは困難です。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YDiversified-financials 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2024/04/03 11:38終値2024/04/03 00:00収益2023/12/31年間収益2023/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋A SPAC I Acquisition Corp. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Apr 04+ 1 more updateNewGenIvf Limited completed the acquisition of A SPAC I Acquisition Corp. (NasdaqCM:ASCA) from A SPAC (Holdings) Acquisition Corp. and others in reverse merger transaction.NewGenIvf Limited entered into a merger agreement to acquire A SPAC I Acquisition Corp. (NasdaqCM:ASCA) from A SPAC (Holdings) Acquisition Corp. and others in reverse merger transaction for $50 million on February 15, 2023. Pursuant to the terms of the merger agreement, the aggregate consideration to be paid to existing shareholders of the Company is $50 million, which will be paid entirely in stock, comprised of newly issued Class A ordinary shares of ASCA at a price of $10.00 per share. Upon the effectiveness of the Acquisition Merger, the issued and outstanding Company Shares will be cancelled and automatically converted into the right to receive, without interest, the applicable portion of the Closing Payment Shares for such number of Company Shares. After the Closing, subject to the terms and conditions set forth in the merger agreement, the Principal Shareholders shall have the right to receive in the aggregate up to an additional 2 million ASCA Class A Ordinary Shares as earnout (subject to equitable adjustment for share splits, share dividends, combinations, recapitalizations and the like after the Closing, including to account for any equity securities into which such shares are exchanged or converted). As a result of the transaction, the combined company is expected to be renamed First Fertility Group Ltd. and remain a publicly listed company on the Nasdaq Stock Market. Following the close of the transaction, the combined company will continue to be led by Siu Wing Fung Alfred as Chairman and founder and Tina Fong as Director and co-founder of NewGen. On June 12, 2023, ASCA entered into a First Amendment to Merger Agreement, pursuant to which NewGen has agreed to provide non-interest bearing loans in an aggregate principal amount of up to $0.56 million to ASCA to fund any amount that may be required in order to further extend the period of time available for ASCA to consummate a business combination and for ASCA’s working capital, payment of professional, administrative and operational fees and expenses, and other purposes. In addition, pursuant to the First Amendment, subject to receipt of at least $140,000 as part of the Loan from NewGen, ASCA agreed to waive its termination rights and the right to receive any Break-up Fee due to NewGen’s failure to deliver the U.S. GAAP Financials by February 28, 2023. The transaction is subject to, among other things, regulatory approvals, the approval by ASCA's shareholders of the transaction and satisfaction or waiver of other customary closing conditions, the Key Personnel shall have executed the employment agreements, the SEC shall have declared the Registration Statement effective and immediately after the closing, ASCA shall have in excess of $5,000,000 in net tangible assets, the directors designated by the NewGenIvf shall have been appointed to the board of directors of the ASCA., additional listing application for the closing payment shares shall have been approved for listing by Nasdaq and additional agreements including Lock-up agreements, the registration rights agreement, voting and support agreements, the employment agreements and the non-competition agreements duly executed by all parties. The NewGen and ASCA Boards of Directors have unanimously approved the proposed transaction, which is expected to be completed in the third quarter of 2023. As of April 11, 2023, ASCA extended the outside date from April 17, 2023 to May 17, 2023 to complete the transaction. As of May 11, 2023, ASCA made a deposit of $90,000 (the “Extension Payment”) to the trust account and extended the period of time the Company has to consummate an initial business combination from May 17, 2023 to June 17, 2023. Following the deposit of the Extension Payment, the amount of funds remaining in the trust account was $38.1 million. As of October 11, 2023, ASCA made a deposit of $20,000 (the “Extension Payment”) to the trust account and extended the period of time the Company has to consummate an initial business combination from October 17, 2023 to November 17, 2023. Following the deposit of the Extension Payment, the amount of funds remaining in the trust account was approximately $39.3 million. As on March 4, 2024, the transaction was approved by shareholders of A SPAC I Acquisition Corp. Giovanni Caruso of Loeb & Loeb LLP acted as legal advisor to A SPAC I Acquisition Corp. (NasdaqCM:ASCA). Guangqin Wei and Chris G. Tang of Jun He Law Offices acted as legal advisor to NewGenIvf Limited. Kalikova & Associates, Haiwen & Partners LLP, DFDL (Thailand) Limited and Ogier acted as legal advisor to A SPAC I Acquisition Corp. (NasdaqCM:ASCA). NewGenIvf Limited completed the acquisition of A SPAC I Acquisition Corp. (NasdaqCM:ASCA) from A SPAC (Holdings) Acquisition Corp. and others in reverse merger transaction on April 3, 2024.
Valuation Update With 7 Day Price Move • Mar 22Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to US$9.08, the stock trades at a trailing P/E ratio of 45.8x. Average trailing P/E is 19x in the Capital Markets industry in the US. Total loss to shareholders of 14% over the past year.
Valuation Update With 7 Day Price Move • Mar 07Investor sentiment improves as stock rises 16%After last week's 16% share price gain to US$11.34, the stock trades at a trailing P/E ratio of 57.2x. Average trailing P/E is 19x in the Capital Markets industry in the US. Total returns to shareholders of 9.0% over the past year.
Board Change • Dec 31High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. Chairman, CEO & CFO Claudius Tsang is the most experienced director on the board, commencing their role in 2021. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Nov 11A SPAC I Acquisition Receives Letter from Nasdaq Due to Not Maintains Minimum of 300 Public Holders for Continued Listing in Accordance Nasdaq Listing Rule 5550(a)(3)On November 7, 2023, A SPAC I Acquisition Corp. (the ‘Company’) received a letter from The Nasdaq Stock Market LLC (‘Nasdaq’), which stated that the Company no longer complies with Nasdaq’s continued listing rules on The Nasdaq Capital Market due to the Company not having maintained a minimum of 300 public holders for continued listing, as required pursuant to Nasdaq Listing Rule 5550(a)(3). In accordance with the Nasdaq listing rules, the Company has 45 calendar days to submit a plan to regain compliance and, if Nasdaq accepts the plan, Nasdaq can grant the Company an extension of up to 180 calendar days from the date of the letter to evidence compliance. The Company plans to submit a compliance plan within the specified period.
お知らせ • Aug 17A SPAC I Acquisition Corp. announced delayed 10-Q filingOn 08/15/2023, A SPAC I Acquisition Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Jun 14A SPAC I Acquisition Corp. announced that it has received $0.2 million in funding from A SPAC (Holdings) Acquisition Corp.A SPAC I Acquisition Corp. announced a private placement of a convertible unsecured promissory note at an issue price of $200,000 for gross proceeds of $200,000 on June 12, 2023. The transaction included participation from returning investor, A SPAC (Holdings) Acquisition Corp. The note shall be payable promptly on demand and, in any event, no later than the date on which the company terminates or consummates an initial business combination. Such note is convertible into warrants having the same terms and conditions as the public warrants, at the price of $1.00 per warrant, at the option of the investor. The note does not bear interest.
お知らせ • May 18A SPAC I Acquisition Corp. announced delayed 10-Q filingOn 05/17/2022, A SPAC I Acquisition Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Apr 01A SPAC I Acquisition Corp. announced delayed annual 10-K filingOn 03/31/2022, A SPAC I Acquisition Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC.